→ Risk Assessment

RASS Annual Business Meeting & Reception

Wednesday, March 24, 2004

6:00 p.m. – 7:30 p.m.

Baltimore Convention Center Room 324

PM3006501513

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Agenda

- Accomplishments for 2003-2004
  - Status of RASS
  - Introduction of new officers
- Next Years Programs and Activities (A. Jarabek)
- RASS Best Manuscript Awards (A. Jarabek)
  - Best Manuscript Advancing Risk Assessment
  - Best Manuscript Demonstrating Risk Assessment Application
- RASS Best Student Abstract Award (K. Krishnan)
- RASS Best Abstract Award (E. Sargent)
- Recognition for Service to RASS
- Presentation by Dr. John Graham
- Open Session for Membership Input
  - Ideas to better serve RASS membership
  - 2004 nomination of symposia workshops, continuing education, etc.
- Concluding comments by Incoming President

PM3006501514

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Status of RASS

- How many members belong: 280
- Budget: $9,180
- Members registered to attend meeting as of March 1: 99
  - Additional revenue: $4,398.57 (estimate)
- SOT 2004 symposia/workshops sponsored: 4
- SOT 2004 CE courses sponsored: 2

PM3006501515

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

2004-2005 RASS Officers

■ President	Annie Jarabek
■ Vice President	Kannan Krishnan
■ Vice President-Elect	Mike Gargas
■ Secretary/Treasurer	Steve Dizio
■ Councilor (2 year)	Deborah Proctor
■ Councilor (1 year)	Lorenz Rhomberg
■ Past President	Ed Sargent

PM3006501516

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Outgoing Officers…

to Whom We Owe Many Thanks

- Councilor — Ed Ohanian
- Past President — Matt Bogdanffy

PM3006501517

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

RASS 2004/05
Program & Activities

- **April 15** is submission deadline for symposia and continuing education
  - Need your input & ideas
  - Evaluate venue attributes that best suit topic:
    - Symposium
    - Workshop
    - Continuing Education
  - Strategize with other specialty sections
    - Primary endorsements allowed: 4
    - Secondary endorsements: Unlimited
- Consider a Contemporary Concepts in Toxicology (CCT) program
  - Longer duration to develop issue / dialogue
  - Couple with support of other organization(s)

PM3006501518

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

RASS 2004/05
Program & Activities *(cont.)*

- SOT long-range plan on the www
  - Specialty section role is prominent
  - Student outreach
    - **Free** membership to specialty sections
    - Student award "challenge"
    - RASS poster / representation at student mixer
- Redesign of www home pages
  - Design support of 5 hours / month by council
  - **New** RASS web page and logo contest
  - Broadcast of special events
  - Suggestions for media contacts, position papers, etc.
- Revised teleconference presentations
  - NAS report on the use of human studies
  - Topics TBD by **YOU** — *please* let us know!

PM3006501519

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

RASS Annual Best Manuscript Competition

- **Nominations by membership**
- Review of relevant journals *published* in past year
  - Toxicol. Sci.
  - Tox. Appl. Pharmacol.
  - Inhal. Toxicol.
  - Human Ecol. Risk Assess.
  - Regul. Toxicol. Pharmacol.
  - Risk Anal.
  - Crit. Rev. Toxicol.
- Chosen by Vice-President & Awards committee
  - "Top ten" fully vetted
  - Scoring criteria: clarity, relevance, and impact

PM3006501520

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

RASS 2004
Best Manuscript Awards Committee

- Matthew Bogdanffy, DuPont Haskell
- Elaine Faustman, Univ. Washington
- Penelope Fenner-Crisp, ILSI
- Annie Jarabek, US EPA
- Raymond Yang, Colorado State Univ.

PM3006501521

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

2004 RASS "Top Ten" Manuscripts

Risk Assessment Application

Beliveau, M; Tardiff, R; Krishnan, K. (2003). Quantitative structure -property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats. *Toxicol. Appl. Pharmacol.* **189**, 221-232.

Boyes, WK; Bercegeay, M; Ali, J S; Krantz, T; McGee, J; Evans, M; Raymer, JH; Bushnell, PJ; Simmons, JE. (2003). Dose -based duration adjustments for the effects of inhaled trichloroethylene on rat visual function. *Toxicol. Sci.* **76**, 121-130.

Clewell, RA; Merrill, EA; Yu, KO; Mahle, D A; Sterner, TR; Matle, DR; Robinson, PJ; Fisher, FW; Gearhart, JM. (2003). Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: A physiologically -based pharmacokinetic analysis of perchlorate and iodide kinetics in the ra t. *Toxicol. Sci.* **73**, 235-255.

Clewell, RA; Merrill, EA; Kyung, KO; Mahle, DA; Sterner, TR; Fisher, JW; Gearhart, JM. Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically -based pharmacokinetic modeling. *Toxicol. Sci.* **73**, 416-436.

Dennison, JE; Andersen, ME; Yang, RS. (2003). Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. *Inhal. Toxicol.* **15(10)**, 961-986.

Conolly, RB; Kimbell, JS; Janszen, D; Schlosser, PM; Kalisak, D; Preston, J; Miller, FJ. (2003). Biologically -motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. *Toxicol. Sci.* 75, 432-447.

Contrera, JF; Matthews, EJ; Benz, DR. (2003). Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E -state indices. *Regul. Toxicol. Pharmacol.* **38(3)**, 243-259.

Gentry, PR; Covington, TR; Clewell, HJ. (2003). Evaluation of the pot ential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. *Regul. Toxicol. Pharmacol.* **38(1)**, 17-26.

Kirman, CR; Sweeney, LM, Meek, ME; Gargas, ML. (2003). Assessing the dose -dependency of allometric s caling performance using physiologically -based pharmacokinetic modeling. *Regul. Toxicol. Pharmacol.* **38(3)**, 345-367.

Lipscomb, JC; Teuschler, LK; Swartout, J; Popken, D; Cox, T; Kedderis, GL. (2003). The impact of cytochrome P450 2E1 -dependent metabolic variance on a risk -relevant pharmacokinetic outcome in humans. *Risk Anal.* **23(6)**, 1221-38.

Merrill, EA; Clewell, RA; Gearhart, JM; Robinson, PJ; Sterner, TR; Yu, KO; Matle, DR; Fisher, JW. (2003). PBPK Predictions of perchlorate distribution and its ef fect on thyroid uptake of radionuclide in the male rat. *Toxicol. Sci.* **73**, 256-269.

Pastino, GM; Kousba, AA, Sultatos, LG; Flynn, EJ. (2003). Derivation of occupational exposure limits based on target blood concentrations in humans. *Regul. Toxicol. Pharmacol.* **37(1)**, 66-72.

Tan, YM; Butterworth, BE; Gargas, ML; Conolly, RB. (2003). Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. *Toxicol. Sci.* **75**, 192-200.

Trohalaki, S; Zellmer, RJ; Pachter, R; Hussain, SM; Frazier, JM. (2002). Risk assessment of high -energy chemicals by in vitro toxicity screening and quantitative structure - activity relationships. *Toxicol. Sci.* **68(2)**, 498-507.

PM3006501522

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

2004 RASS "Top Ten" Manuscripts

Advancing Risk Assessment

Bennett, DH; Margni, MD; McKone, TE; Jolliet, O. (2002). Intake fraction for multimedia pollutants: A tool for life cycle analysis and comparative risk assessment. *Risk Anal.* **22(5)**, 905-918.

Calabrese, EJ; Baldwin, LA. (2003). The hormetic dose-response model is more common than the threshold model in toxicology. *Toxicol. Sci.* **71**, 246-250.

Gentry, PR; Hack, CE; Haber, L; Maier, A; Clewell, HJ. (2002). An approach for the quantitative consideration of genetic polymorphisms in chemical risk assessment: Examples with warfarin and parathion. *Toxicol. Sci.* 70(1), 120-139.

Hofmann, W; Asgharian, B. (2003). The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. *Toxicol. Sci.* **73**, 448-456.

Judd, NL; Griffith, WC; Takaro, T; Faustman, EM. (2003). A model for optimization of biomarker testing frequency to minimize disease and cost: Example of beryllium sensitization testing. *Risk Anal.* **23(6),** 1211.

Leakey, JEA; Seng, J; Allaben, WT. (2003). Body weight considerations in the B6C3F1 mouse and the use of dietary control to standardize background tumor incidence in chronic bioassays. *Toxicol. Appl. Pharmacol*, **193(2),** 237-265.

Pelekis, M; Nicolich, MJ; Gauthier, JS. (2003). Probabilistic framework for the estimation of adult and child toxicokinetic interspecies uncertainty factors. *Risk Anal.*, **23(6)**, 1239.

Plowchalk, DR; Teeguarden, J. (2002) Development of a physiologically-based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. *Toxicol. Sci,*. 69, 60-78.

Price, PS; Conolly, RB; Chaisson, CF; Gross, EA; Young, JS. (2003). Modeling inter-individual variation in physiological factors used in PBPK models of humans. *CRC Crit. Rev. Toxicol.* **33**, 469-503.

Sarangapani, R; Gentry, PR; Covington, TR; Teeguarden, JG; Clewell, HJ. (2003). Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. *Inhal. Toxicol.* **15(10),** 987-1016.

Whitaker, SY; Portier, CJ. (2002) A controlled growth and differentiation model for non-monotonic responses. *Human and Ecol. Risk Assess.* **8(7),** 1739-1755.

PM3006501523

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Risk Assessment Specialty Section 2004

Best Manuscript Advancing Risk Assessment:

Plowchalk, DR, Teeguarden, J. (2002). Development of a physiologically-based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. *Toxicol. Sci.* **69**, 60-78.

Best Manuscript Demonstrating a Risk Assessment Application:

Connolly, RB; Kimbell, JS: Janszen, D; Schlosser, PM; Kalisak, D; Preston, J; Miller, FJ. (2003). Biologically-motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. *Toxicol. Sci.* **75**, 432-447.

PM3006501524

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Risk Assessment Specialty Section 2004

The Risk Assessment Specialty Section honors the Following Competition Winners:

Best Student Abstract Award

Impaired Signal Trafficking Underlies Failed On-Demand Liver Tissue Repair Upon Hepatotoxic Challenge in Type 2 Diabetes (Abstract No. 512)

Authors: S.P. Sawant, A.V. Dnyanmote, J.R. Latendresse and H.M. Mehendale.

PM3006501525

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Risk Assessment Specialty Section 2004

Best Abstract Award Runners Up

Abstract Title	Authors	Abstract No.
Application of a PBPK model to aid in understanding the relative potencies (REPs) of dioxin-like chemicals.	L. Birnbaum, M. DeVito M and C. Emond	1761
Identification of interindividual variation in aflatoxin metabolizing enzymes using human urinary data.	B. Dash, E. Afriyie-Gyawu, W. Porter, H. Huebner and T. Phillips	864
Computational model for radiation-induced cell death at low doses in the developing neocortex.	N. DeFrank, W. Griffith, J. Gohlke and E. Faustman	1315
Modeling risks from intermittent exposures to lead: effect of exposure model averaging time.	M. Follansbee, R. Lorenzana, J. Klotzbach, G. Diamond and R. Troast.	743
Use of human and animal PBPK models in risk assessment for perchlorate.	D. Mattie, E. Sterner, E. Merrill, R. Clewell, Q. Zhao, J. Strawson and M. Dourson	1757
Issues in the validation of PBPK models for risk assessment: an example with perchloroethylene.	J. Kester, HJ Clewell and R. Gentry	1763
Scientific rationale for the derivation of a reference dose (RfD) for perchlorate.	H. Leung, D. Proctor, A. Madl, S. Hays and E. Cohen	1756
Pharmacokinetic (PK)/pharmacodynamic (PD) relationship of PCB126 under the conditions of modified Ito medium-term liver bioassay.	M. Lohitnavy, L. Chubb, O. Lohitnavy, C. Yang, J. Homburg, J. Campain and RSH Yang	1319
Estimation of the magnitude of the pharmacokinetic component of interindividual variability factor using a probability bounds approach.	A. Nong and K. Krishnan	1770
A pragmatic method for simulating the pharmacokinetics of interacting chemicals in mixtures: a case study with toluene in mixtures.	K. Price and K. Krishnan	2032
Development of a risk assessment to evaluate human health risks from exposure to tebuconazole as a wood preservative.	B. Shipp, E. Dube, B. Beck, M. Seeley, K. Radaloff, S. Schettler and C. Petito Boyce	749
Determining the respiratory bioavailability of water-soluble vapors using PBPK modeling and a combined gas uptake inhalation, plethysmography and blood sampling system.	A. Woodstock, R. Corley, T. Poet, J. Soelberg, J. Teeguarden, W. Faber, B. Francis and H. Wu	2103
Dialkyl phosphates (DAP) in produce confound biomonitoring in organophosphate	X. Zhang and R. Krieger	528

PM3006501526

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001

Risk Assessment Specialty Section 2004

The Risk Assessment Specialty Section honors the Following Competition Winners:

Best Abstract Award

Approaches for Converting Adult Dose to Children of Various Age Groups: Relevance for the Risk Assessment of Environmental Chemicals (Abstract No. 1770)

Authors: Gohore Bi and K. Krishnan

PM3006501527

Source: https://www.industrydocuments.ucsf.edu/docs/hmhj0001